Your browser is no longer supported. Please, upgrade your browser.
Immunic, Inc.
Index- P/E- EPS (ttm)-3.75 Insider Own1.50% Shs Outstand25.32M Perf Week-1.71%
Market Cap211.29M Forward P/E- EPS next Y-3.45 Insider Trans0.96% Shs Float19.79M Perf Month-0.81%
Income-82.90M PEG- EPS next Q-0.92 Inst Own50.60% Short Float4.58% Perf Quarter-12.50%
Sales- P/S- EPS this Y37.90% Inst Trans38.44% Short Ratio4.47 Perf Half Y-36.27%
Book/sh5.75 P/B1.50 EPS next Y8.10% ROA-53.90% Target Price54.50 Perf Year-50.46%
Cash/sh4.50 P/C1.91 EPS next 5Y15.50% ROE-59.00% 52W Range6.96 - 28.21 Perf YTD-43.69%
Dividend- P/FCF- EPS past 5Y49.20% ROI- 52W High-69.48% Beta2.00
Dividend %- Quick Ratio11.60 Sales past 5Y- Gross Margin- 52W Low23.71% ATR0.62
Employees28 Current Ratio11.60 Sales Q/Q- Oper. Margin- RSI (14)41.31 Volatility8.08% 7.12%
OptionableYes Debt/Eq0.00 EPS Q/Q-8.60% Profit Margin- Rel Volume0.69 Prev Close9.19
ShortableYes LT Debt/Eq0.00 EarningsNov 04 BMO Payout- Avg Volume202.52K Price8.61
Recom1.60 SMA20-9.94% SMA50-4.20% SMA200-28.38% Volume138,971 Change-6.31%
Apr-15-21Initiated Aegis Capital Buy $55
Mar-24-21Initiated JMP Securities Mkt Outperform $55
Oct-02-20Initiated SVB Leerink Outperform $45
Aug-26-20Initiated Piper Sandler Overweight $71
Aug-07-20Resumed ROTH Capital Buy $64
Jul-20-20Initiated BMO Capital Markets Outperform $40
Jun-05-20Initiated Wedbush Outperform $59
May-11-20Initiated H.C. Wainwright Buy $45
Mar-25-20Initiated ROTH Capital Buy $44
Jul-11-19Initiated Chardan Capital Markets Buy $40
Nov-23-21 06:30AM  
Nov-18-21 04:01PM  
Nov-04-21 06:30AM  
Nov-01-21 06:30AM  
Oct-27-21 06:30AM  
Oct-14-21 06:30AM  
Oct-11-21 09:24AM  
Sep-30-21 06:30AM  
Sep-28-21 06:30AM  
Sep-22-21 12:14PM  
Sep-08-21 06:30AM  
Aug-11-21 04:53AM  
Aug-06-21 06:30AM  
Aug-03-21 06:30AM  
Jul-19-21 04:01PM  
Jul-15-21 06:04PM  
Jul-14-21 04:01PM  
Jul-12-21 06:30AM  
Jul-01-21 11:07AM  
Jun-28-21 06:30AM  
Jun-10-21 06:30AM  
Jun-01-21 06:30AM  
May-13-21 02:01AM  
May-06-21 06:30AM  
Apr-15-21 06:30AM  
Apr-13-21 06:30AM  
Mar-31-21 08:50AM  
Mar-24-21 12:26PM  
Mar-19-21 04:20AM  
Mar-02-21 06:30AM  
Feb-18-21 08:26AM  
Feb-17-21 08:49AM  
Feb-11-21 06:30AM  
Jan-05-21 06:30AM  
Dec-14-20 06:30AM  
Nov-24-20 06:30AM  
Nov-17-20 06:30AM  
Nov-10-20 06:30AM  
Nov-05-20 04:01PM  
Nov-02-20 12:26PM  
Oct-20-20 12:15PM  
Oct-02-20 10:41AM  
Sep-29-20 06:30AM  
Sep-28-20 06:30AM  
Sep-11-20 06:30AM  
Sep-08-20 06:30AM  
Aug-26-20 01:51PM  
Aug-20-20 08:00AM  
Aug-10-20 06:30AM  
Aug-04-20 08:29PM  
Aug-03-20 04:15PM  
Aug-02-20 03:00PM  
Jul-30-20 04:15PM  
Jul-27-20 06:30AM  
Jul-05-20 06:02AM  
Jun-22-20 06:30AM  
Jun-15-20 06:30AM  
Jun-11-20 08:32AM  
Jun-10-20 01:37PM  
Jun-09-20 07:39PM  
Jun-05-20 09:56AM  
May-29-20 06:30AM  
May-19-20 06:30AM  
May-15-20 10:03AM  
May-14-20 11:44AM  
May-13-20 04:01PM  
May-08-20 06:30AM  
Apr-23-20 09:03AM  
Apr-22-20 07:51AM  
Apr-21-20 04:01PM  
Apr-17-20 05:00PM  
Mar-16-20 04:01PM  
Feb-11-20 06:30AM  
Jan-08-20 06:30AM  
Dec-04-19 06:30AM  
Nov-25-19 06:30AM  
Nov-19-19 06:30AM  
Nov-07-19 04:01PM  
Nov-05-19 06:30AM  
Oct-17-19 08:45AM  
Oct-15-19 06:30AM  
Oct-10-19 04:01PM  
Sep-30-19 06:30AM  
Sep-18-19 06:30AM  
Sep-11-19 06:30AM  
Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and other chronic inflammatory and autoimmune diseases, as well as to treat coronavirus disease. The company is also developing IMU-935, an inverse agonist of ROR?t; and IMU-856 for the restoration of the intestinal barrier function in patients suffering from diseases, such as inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor induced colitis, and other intestinal barrier function diseases. Immunic, Inc. is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Whaley GlennPFO and PAOAug 10Buy9.851,50014,7753,500Aug 11 09:05 AM
Vitt DanielPresident and CEOAug 10Buy9.601,0009,600363,877Aug 11 09:04 AM
Nash DuaneExecutive ChairmanAug 10Buy9.801,0009,80015,032Aug 11 09:02 AM
Nash DuaneExecutive ChairmanMay 12Buy12.754,00051,00014,032May 12 04:31 PM
Muehler AndreasChief Medical OfficerMar 02Buy15.5410,006155,493294,486Mar 15 05:05 PM
Whaley GlennPFO and PAOMar 02Buy16.481,00016,4802,000Mar 03 04:31 PM